Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.

Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study Group.

Pituitary. 2015 Oct;18(5):604-12. doi: 10.1007/s11102-014-0618-1.

2.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27.

PMID:
24533697
3.

A 12-month phase 3 study of pasireotide in Cushing's disease.

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group.

N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.

5.
6.

No effect of bicarbonate-induced alkalosis on urea synthesis in normal man.

Bjerrum K, Vilstrup H, Almdal TP, Ostergaard Kristensen L.

Scand J Clin Lab Invest. 1990 Apr;50(2):137-41.

PMID:
2160122
7.

Lactoferrin receptors in normal and leukaemic human blood cells.

Birgens HS, Karle H, Hansen NE, Ostergaard Kristensen L.

Scand J Haematol. 1984 Sep;33(3):275-80.

PMID:
6095437

Supplemental Content

Loading ...
Support Center